Taconic Biosciences supplies the animals that other laboratories run studies in. Headquartered in Rensselaer, New York, it breeds and sells genetically engineered mice and rats, generates new models to order, and manages client colonies, across seven facilities in the United States and Europe.[S3][S4][S5] It is a model provider rather than a contract research organization, and that distinction determines what a sponsor can place here: strain generation, breeding, health status and colony logistics, not efficacy or safety studies. The catalogue is stated at more than 4,600 mouse and rat models.[S4] The company also holds an unusual position in one niche, describing itself as the only proven commercial source of germ-free mice, a line of work it dates to 1961.[S2]
Services relevant to US drug developers
Model supply and custom model generation
Custom models are generated by gene editing, embryonic stem cell targeting and pronuclear injection, with a doctoral-level project manager assigned to each programme, and the company states it has produced roughly 5,000 custom models over the last fifteen years.[S5] The catalogue side covers standard inbred, outbred and hybrid strains, immunodeficient lines, diet-induced models, oncology and immuno-oncology models including syngeneic and spontaneous tumour lines, neurobiology models for Alzheimer disease and Parkinson disease research, and inflammatory bowel disease models.[S2][S4] The immunodeficient portfolio is built on the NOG background, extended with humanized immune system versions and with Fc receptor null variants.[S2] For an immuno-oncology programme, the choice of humanized model is usually a bigger determinant of what the study can show than the study design itself, so it is worth resolving early with the supplier.
Germ-free and defined microbiome animals
Gnotobiotic work is offered as a service that generates and maintains mice carrying a defined, custom microbiome, and the company cites more than fifty years of experience in the area.[S5] Related to this is a tiered set of health standards, from germ-free at the most stringent end through defined flora, opportunist free and restricted flora, to murine pathogen free, where a listed set of opportunistic bacteria is tolerated.[S7] Every animal is stated to be tested under the company own health monitoring system.[S8] Health standard is not a quality ranking. It is a specification, and a study comparing animals from different tiers, or from different suppliers, may not be comparable at all.
Colony management and adjacent services
Colony management covers housing, health monitoring, animal conditioning, accelerated backcrossing and support for importing an existing colony.[S5] Embryology services provide rederivation and rapid expansion, and cryopreservation with recovery is offered as risk management for a line.[S5] Genotyping and molecular characterization are performed throughout breeding by an in-house genetics team.[S5] Surgical services including cannulation are performed by trained surgeons under board-certified veterinary oversight.[S5] Additional named capabilities include flow cytometry, gene expression analysis and protein analysis.[S2]
Compound profiling, explicitly non-GLP
One service does touch compound testing. The company offers profiling using its own absorption, distribution, metabolism, excretion and toxicity model panels, which include xenoreceptor, cytochrome P450 and transporter lines, and it describes this work as non-GLP.[S9] That is an explicit statement rather than an absence of one, and it is the useful kind: a sponsor knows immediately that these data support decision-making rather than a submission that requires a study conducted under the good laboratory practice regulation.[R2] The same page names carcinogenicity models including the TK-NOG and TSG-p53 lines and the rasH2 mouse.[S9] Those models are supplied for studies run elsewhere.
Quality, compliance, and animal welfare (as stated by the company)
The company states that it was the first commercial breeder to receive full AAALAC International accreditation, and its history names accreditation of two sites in 2006.[S2][S6] It states that all animal operations are overseen by board-certified veterinarians and a standing Institutional Animal Care and Use Committee, that the committee reviews anaesthetic and analgesic use in surgical services, and that it practises the three Rs of replacement, reduction and refinement.[S5][S6] Memberships in laboratory animal science associations in the United States and Europe are listed.[S6] No USDA registration statement and no Animal Welfare Assurance statement were found on the pages reviewed; that is an absence in those pages, not a finding about the company status. AAALAC International accreditation is a voluntary evaluation of an institution's animal care and use program, re-evaluated every three years,[R3] and USDA registration and an OLAW Animal Welfare Assurance relate to the Animal Welfare Act and the PHS Policy respectively;[R4][R5] none of these establishes GLP compliance, which applies to individual studies.[R2] FDA does not approve or certify laboratories; registration with FDA does not denote approval.[R6] This profile does not evaluate the animal care programme.
History and ownership
The company gives three different starting points for itself, and none is presented here as the founding year. Its history page opens in 1940, with a predecessor business started by Robert K. Phelan in a garage in Canajoharie, New York.[S2] Its own tagline dates the business to 1949.[S1] The company description used in a 2022 acquisition announcement states 1952, the year operations began in Germantown, New York.[S10] The name changed from Taconic Farms to Taconic Biosciences in September 2014.[S2] Ownership has moved twice recently: H.I.G. Capital acquired the company in 2019, and Avista Capital Partners acquired it from H.I.G. on November 1, 2022, with terms not disclosed.[S2][S10] The chief executive named at that acquisition is not the one listed on the later management page, and no announcement of the change was located.[S10][S11]
Company facts
Legal name
Taconic Biosciences, Inc.; known as Taconic Farms until September 2014[S2]
Headquarters
5 University Place, Rensselaer, NY 12144, United States[S3]
Founding year
Stated three ways by the company: a 1940 predecessor, a 1949 tagline, and 1952 in acquisition materials[S1][S2][S10]
Ownership
Private; acquired by Avista Capital Partners from H.I.G. Capital on November 1, 2022[S10]
FDA ? "Is It Really FDA Approved?" (FDA does not approve health care providers, including laboratories; registration does not denote approval); FDA Compliance Program 7348.808 (GLP inspections of nonclinical laboratories). https://www.fda.gov/consumers/consumer-updates/it-really-fda-approved (accessed 2026-09-03)
3 Recommended Contract Research Organizations for Non-Clinical Studies
— by Target goal and Expertise
In drug discovery, the quality and efficiency of non-clinical studies have a direct impact on clinical success rates, development costs, and overall length of time required in R&D.
In recent years, there has been more demand for clinically relevant data, globally accepted reliability, and accurate early-stage screening.
Thus, it is more important than ever to select the right CRO (Contract Research Organization) for strategic approach.
In this article, we highlight three CROs with proven technical capabilities, expertise, and long standing track records. These are our TOP 3 choices based on their capabilities and the specific target goals of the researchers for their non-clinical studies.
Pharmacology (Efficacy) Studies Replicate unknown pathological models and Discovery to clinically oriented drug evaluation
SMC Laboratories, Inc.
Reference: SMC Laboratories, Inc. official website (https://www.smccro-lab.com/jp/)
SMC Laboratories, Inc. has established a disease models using patented mouse technologies.
The company has established proprietary pathological models—particularly in liver disease and fibrosis—and continues to expand their approach across a wide range of models in cancer, inflammation, and metabolic diseases.
From exploratory research to clinically oriented efficacy evaluation, SMC offers customized study designs, dosing strategies, and evaluation analysis tailored to each project.
Their collaborative approach allows researchers to discuss and refine study plans together with SMC’s expert scientists.
With flexible small-scale study options and strong technical support, SMC Laboratories, Inc. is an ideal partner for start-ups, biotech ventures, and academic institutions alike.
Safety Studies Comprehensive Safety Evaluation for FIH Applications
Labcorp Holdings Inc. (Labcorp Drug Development)
Reference: Labcorp Holdings Inc. official website (https://jp.labcorp.com/)
Labcorp Holdings Inc. provides a fully integrated GLP testing system aligned with international regulatory standards, including FDA, EMA, and PMDA requirements.
All studies are conducted under ICH-compliant quality assurance, making it ready for data submission.
The company has extensive expertise in long-term toxicity studies such as Segment I–III reproductive and carcinogenicity studies, as well as 2-year chronic toxicity assessments.
Labcorp Holdings Inc.’s comprehensive approach enables sponsors to efficiently outsource the entire preclinical package from toxicology, toxicokinetic (TK), and safety pharmacology study design to execution. This accelerates a path to First-in-Human (FIH) trials.
For most of the global drug developers, this all-in-one service structure minimizes cost, risk, and expedite the time before advancing to clinical phase.
Pharmacokinetic (PK/PD) Studies High-Precision Bioanalysis for Clinically Predictive PK/PD Evaluation
PhoenixBio Co., Ltd.
Source: PhoenixBio Co., Ltd. Official Website (https://phoenixbio.co.jp/)
PhoenixBio Co., Ltd. offers pharmacokinetic and hepatic metabolism studies using their proprietary PXB-mouse®, a humanized-liver chimeric mouse model. This platform enables the acquisition of data with high clinical correlation in ADME, drug–to–drug interaction studies, bridging the gap between preclinical and clinical stages.
With advanced LC-MS/MS-based bioanalysis, PhoenixBio Co., Ltd. provides a seamless workflow from plasma concentration measurement and metabolite identification to quantitative validation.
The company offers an integrated evaluation analysis covering pharmacokinetics, hepatotoxicity, and safety with flexibility to accommodate complex modalities such as oligonucleotide and middle-molecule therapeutics.
For compounds where hepatic metabolism is a development bottleneck—or where quantitative, reproducible exposure data are critical—PhoenixBio Co., Ltd. delivers unmatched analytical precision and consistency.
Japanese
